ISBI 2020 Patrons & Supporters

Special Thanks

The conference organizers gratefully acknowledge the generous support provided by the following


Canon Medical Research


Canon Medical Research USA, Inc. (CMRU) and Canon Medical Research Europe (CMRE) are R&D centers for Canon Medical Systems, a leading company in medical imaging, which offers a full range of diagnostic imaging solutions including CT, MR, X-Ray, Ultrasound and Healthcare Informatics across the globe.

Canon Medical Research USA, Inc. (CMRU) is a multi-modality R&D center that designs the next generation medical imaging systems. Headquartered in Chicago, with offices in Cleveland, and San Francisco, CMRU is the center of excellence for system development, imaging algorithms and embedded software, etc. Throughout the years, we have delivered many new features to flagship products across modalities offered by Canon Medical System. Our mission is to drive healthcare solutions that result in a higher quality of life in an atmosphere that values all people and ideas. Together we work for a healthier future.

Canon Medical Research Europe is a leading medical software research and development center of excellence, generating breakthrough technologies and valuable intellectual property for Canon Medical Systems. Based in the diverse city of Edinburgh we employ over 130 people working as Software Engineers, Scientists, Clinical Specialists, Testers and Business Support and are part of a global corporation headquartered in Japan. We develop next generation medical imaging software, technology components and AI solutions that integrate with Canon Medical scanners and diagnostic healthcare systems which are installed in hospitals and healthcare centers across the globe.




IDx is a leading AI diagnostics company on a mission to transform the quality, accessibility, and affordability of healthcare. Founded in 2010 by a team of world-renowned clinician scientists, the company is focused on developing clinically-aligned autonomous AI that detect disease in medical images. By enabling diagnostic assessment in primary care settings, IDx aims to increase patient access to high-quality, affordable disease detection.

The company’s first product, IDx-DR, is an FDA-cleared autonomous AI-based diagnostic system designed for use at the front lines of care to detect diabetic retinopathy. IDx is developing additional AI-based diagnostic systems for the detection of macular degeneration, glaucoma, Alzheimer’s disease, cardiovascular disease, and stroke risk. 


IBM Research